04 September 2019
Visiongain has launched a new pharma report Acute Repetitive Seizures Market Forecast 2019-2029: By Product (USL-261, NRL-1, AZ-002, Diastat Rectal Gel), By Region and Segment Forecasts.
The global Acute Repetitive Seizures market is poised for rapid growth between 2019 and 2029. High unmet medical clinical for patients, as well as caregivers and the availability of an advanced product pipeline are some of the main factors that should favor market growth. Drug therapy is effective for most patients with cluster convulsions. However, there are a significant number of therapeutic challenges and unmet medical needs including drug-induced seizures, adverse reactions and a lack of anti-epileptic agents that can prevent the development of convulsions and its comorbidities.
The market is currently driven by generic drugs that mainly include oral benzodiazepines (diazepam and lorazepam). Rectal diazepam is the only drug approved for use in the United States and buccal midazolam in the European Union. Other drugs, such as diazepam (oral and intramuscular), midazolam (oral, intranasal, intramuscular), lorazepam (oral, intranasal, sublingual) and progesterone are mainly used off label. The market should be consolidated with a few large companies and high market shares.
Leading companies featured in the report include UCB S.A. Belgium, Neurelis, Valeant Pharmaceuticals North America LLC., Alexza Pharmaceuticals, VERITON PHARMA and others
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.